TY - JOUR T1 - PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 2501 LP - 2509 DO - 10.21873/anticanres.15028 VL - 41 IS - 5 AU - KAKERU HISAKANE AU - MASAHIRO SEIKE AU - TEPPEI SUGANO AU - KUNIKO MATSUDA AU - SHINOBU KUNUGI AU - SHINJI NAKAMICHI AU - MASARU MATSUMOTO AU - AKIHIKO MIYANAGA AU - RINTARO NORO AU - YUJI MINEGISHI AU - KAORU KUBOTA AU - AKIHIKO GEMMA Y1 - 2021/05/01 UR - http://ar.iiarjournals.org/content/41/5/2501.abstract N2 - Background/Aim: Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive tumor that is resistant to treatment. The expression and prognostic value of programmed cell death-ligand 1 (PD-L1) and its association with epithelial–mesenchymal transition (EMT) in PPC remains unclear. Patients and Methods: The expression of PD-L1 and EMT markers, such as E-cadherin, vimentin, zinc finger E-box-binding homeobox 1 (ZEB-1), and cellular mesenchymal–epithelial transition (c-Met) was evaluated by immuno - histochemistry in 16 patients with PPC who underwent surgical resection. Results: The expression of PD-L1 varied between carcinomatous and sarcomatous areas. Positive correlations between PD-L1 and vimentin expression in carcinomatous areas (r=0.668, p=0.005) and PD-L1 and ZEB-1 expression in sarcomatous areas (r=0.562, p=0.023) were found. High PD-L1 and ZEB-1 expression in sarcomatous areas predicted poor survival (p=0.045 and p=0.012, respectively). Conclusion: PD-L1 expression associated with ZEB1 expression in the sarcomatoid component of patients with PPC may be useful for predicting patient prognosis. ER -